<p>在最新的季度中，5 位分析师对 Harmony Biosciences Hldgs（纳斯达克：HRMY）提供了评级，展现出看涨和看跌的不同观点。</p>
<p>以下表格总结了他们最近的评级，提供了过去 30 天情绪变化的概览，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师分析的 12 个月价格目标提供了见解，平均目标为 46.8 美元，最高预估为 55.00 美元，最低预估为 42.00 美元。当前平均目标较之前的 45.40 美元增加了 3.08%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png"/></p>
<h2>解读分析师评级：深入分析</h2>
<p>通过对最近分析师行动的全面分析，描绘出 Harmony Biosciences Hldgs 在金融专家中的认知。以下总结了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>上调</td>
<td>中立</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>下调</td>
<td>买入</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上调</td>
<td>超越大盘</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright  Co.</td>
<td>维持</td>
<td>买入</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 Harmony Biosciences Hldgs 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 “超越大盘” 到 “跑输大盘”。这些评级传达了对 Harmony Biosciences Hldgs 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 深入分析，分析师提供对 Harmony Biosciences Hldgs 股票未来价值的估计。这一分析揭示了分析师预期随时间的变化。</li>
</ul>
<p>为了全面了解 Harmony Biosciences Hldgs 的市场表现，请将这些分析师评估与重要财务指标结合起来。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 Harmony Biosciences Hldgs 的分析师评级。</p>
<h2>关于 Harmony Biosciences Hldgs 的所有信息</h2>
<p>Harmony Biosciences Holdings Inc 是一家商业阶段的制药公司，专注于为生活在罕见神经疾病中的患者开发和商业化疗法，以满足未满足的医疗需求。该公司的产品 WAKIX（匹托利桑）是一种具有新颖作用机制的分子，专门设计用于通过结合 H3 受体来增加大脑中的组胺信号，并用于治疗成年嗜睡症患者的肌无力发作。其管线中的其他药物候选者包括匹托利桑、HBS-102（MCHR1 拮抗剂）、BP1.15205（食欲素-2 受体激动剂）、ZYN002（大麻二酚凝胶）、EPX-100（氯米扎氯盐酸盐）和 EPX-200（洛卡特普）等。</p>
<h3>关键指标：Harmony Biosciences Hldgs 的财务健康状况</h3>
<p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相较于同行相对较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
<p><strong>收入增长：</strong> Harmony Biosciences Hldgs 在 3M 的卓越表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>28.71%</strong> 的显著收入增长率。这标志着公司顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> Harmony Biosciences Hldgs 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>21.24%</strong>，展示了强大的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> Harmony Biosciences Hldgs 的 ROE 超越行业基准，达到 <strong>6.33%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
<p><strong>资产回报率（ROA）：</strong> Harmony Biosciences Hldgs 的 ROA 超越行业基准，达到 <strong>4.39%</strong>。这表明其资产管理高效，财务健康状况良好。</p>
<p><strong>债务管理：</strong> Harmony Biosciences Hldgs 的债务与股本比率低于平均水平，为 <strong>0.2</strong>，采取了谨慎的财务策略，表明其在债务管理方面的平衡方法。</p>
<h2>理解分析师评级的相关性</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>一些分析师还提供有助于决策的指标预测，如收益、收入和增长预期，以进一步指导如何处理某些股票代码。需要记住的是，尽管股票和行业分析师是专家，但他们也是人类，只能将自己的信念预测给交易者。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

HRMY

<p>在最新的季度中，分析师对 Harmony Biosciences Hldgs（NASDAQ:HRMY）给出了不同的评级。12 个月的平均目标价为 46.8 美元，比 45.40 美元上涨了 3.08%。主要分析师进行了各种调整：瑞银将评级上调至中性（46.00 美元），Truist 将评级下调至买入（45.00 美元），瑞穗将评级上调至跑赢大盘（46.00 美元），其他分析师则维持其评级。Harmony 的市值低于行业平均水平，但其报告的收入增长为 28.71%，净利润率为 21.24%。该公司专注于罕见神经疾病的治疗，财务状况稳健，债务管理谨慎</p>

<p>In the latest quarter, 5 analysts provided ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，5 位分析师对 Harmony Biosciences Hldgs（纳斯达克：HRMY）提供了评级，展现出看涨和看跌的不同观点。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>以下表格总结了他们最近的评级，提供了过去 30 天情绪变化的概览，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $46.8, a high estimate of $55.00, and a low estimate of $42.00. This current average has increased by 3.08% from the previous average price target of $45.40.</p>
<div class="lb-trans"><p>分析师分析的 12 个月价格目标提供了见解，平均目标为 46.8 美元，最高预估为 55.00 美元，最低预估为 42.00 美元。当前平均目标较之前的 45.40 美元增加了 3.08%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770832830_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解读分析师评级：深入分析</h2>
</div><p>A clear picture of Harmony Biosciences Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的全面分析，描绘出 Harmony Biosciences Hldgs 在金融专家中的认知。以下总结了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>上调</td>
<td>中立</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>下调</td>
<td>买入</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上调</td>
<td>超越大盘</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright  Co.</td>
<td>维持</td>
<td>买入</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Harmony Biosciences Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Harmony Biosciences Hldgs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 Harmony Biosciences Hldgs 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 “超越大盘” 到 “跑输大盘”。这些评级传达了对 Harmony Biosciences Hldgs 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 深入分析，分析师提供对 Harmony Biosciences Hldgs 股票未来价值的估计。这一分析揭示了分析师预期随时间的变化。</li>
</ul>
</div><p>To gain a panoramic view of Harmony Biosciences Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了全面了解 Harmony Biosciences Hldgs 的市场表现，请将这些分析师评估与重要财务指标结合起来。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Harmony Biosciences Hldgs analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Harmony Biosciences Hldgs 的分析师评级。</p>
</div><h2>All You Need to Know About Harmony Biosciences Hldgs</h2>
<div class="lb-trans"><h2>关于 Harmony Biosciences Hldgs 的所有信息</h2>
</div><p>Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings Inc 是一家商业阶段的制药公司，专注于为生活在罕见神经疾病中的患者开发和商业化疗法，以满足未满足的医疗需求。该公司的产品 WAKIX（匹托利桑）是一种具有新颖作用机制的分子，专门设计用于通过结合 H3 受体来增加大脑中的组胺信号，并用于治疗成年嗜睡症患者的肌无力发作。其管线中的其他药物候选者包括匹托利桑、HBS-102（MCHR1 拮抗剂）、BP1.15205（食欲素-2 受体激动剂）、ZYN002（大麻二酚凝胶）、EPX-100（氯米扎氯盐酸盐）和 EPX-200（洛卡特普）等。</p>
</div><h3>Key Indicators: Harmony Biosciences Hldgs's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：Harmony Biosciences Hldgs 的财务健康状况</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相较于同行相对较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
</div><p><strong>Revenue Growth:</strong> Harmony Biosciences Hldgs's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>28.71%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Harmony Biosciences Hldgs 在 3M 的卓越表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>28.71%</strong> 的显著收入增长率。这标志着公司顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Harmony Biosciences Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>21.24%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Harmony Biosciences Hldgs 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>21.24%</strong>，展示了强大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Harmony Biosciences Hldgs's ROE excels beyond industry benchmarks, reaching <strong>6.33%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Harmony Biosciences Hldgs 的 ROE 超越行业基准，达到 <strong>6.33%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> Harmony Biosciences Hldgs's ROA excels beyond industry benchmarks, reaching <strong>4.39%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Harmony Biosciences Hldgs 的 ROA 超越行业基准，达到 <strong>4.39%</strong>。这表明其资产管理高效，财务健康状况良好。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.2</strong>, Harmony Biosciences Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Harmony Biosciences Hldgs 的债务与股本比率低于平均水平，为 <strong>0.2</strong>，采取了谨慎的财务策略，表明其在债务管理方面的平衡方法。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<div class="lb-trans"><p>一些分析师还提供有助于决策的指标预测，如收益、收入和增长预期，以进一步指导如何处理某些股票代码。需要记住的是，尽管股票和行业分析师是专家，但他们也是人类，只能将自己的信念预测给交易者。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

Harmony Biosciences Hldgs 在分析师眼中的地位如何